Oliver Gross Selected Research

Ramipril (Altace)

6/2021	Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome.
1/2020	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.
2/2014	Challenges for academic investigator-initiated pediatric trials for rare diseases.
1/2012	Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.
7/2004	Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
2/2003	Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oliver Gross Research Topics

Disease

40	Hereditary Nephritis (Alport Syndrome) 12/2023 - 04/2000
25	Proteinuria 01/2022 - 02/2003
21	Fibrosis (Cirrhosis) 01/2023 - 02/2003
15	Renal Insufficiency (Renal Failure) 11/2022 - 02/2003
14	Chronic Kidney Failure (Chronic Renal Failure) 12/2023 - 02/2003
10	Inflammation (Inflammations) 12/2023 - 08/2005
7	Chronic Renal Insufficiency 01/2023 - 07/2004
6	Inborn Genetic Diseases (Disease, Hereditary) 01/2020 - 04/2000
6	Kidney Diseases (Kidney Disease) 01/2019 - 01/2012
6	Hearing Loss (Hearing Impairment) 06/2017 - 04/2000
4	Disease Progression 01/2020 - 04/2010
3	Albuminuria 12/2023 - 01/2020
3	Atrophy 01/2023 - 04/2005
3	COVID-19 08/2022 - 01/2021
3	Hypertension (High Blood Pressure) 01/2019 - 08/2005
3	Hematuria 04/2012 - 07/2006
3	Nephritis 12/2010 - 04/2000
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2022 - 07/2006
2	Hypoxia (Hypoxemia) 01/2021 - 01/2011
2	Glomerulonephritis 01/2021 - 10/2014
2	IGA Glomerulonephritis (IGA Nephropathy) 01/2018 - 04/2010
2	Uremia 01/2017 - 07/2004
2	Dyslipidemias (Dyslipidemia) 09/2014 - 09/2009
1	Fournier Gangrene 05/2024
1	Pain (Aches) 07/2023
1	Hereditary Corneal Dystrophies 06/2023
1	Benign Familial Hematuria 01/2022
1	Hyperkalemia 06/2021
1	Hypoalbuminemia 01/2021
1	Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome) 01/2021
1	Hemorrhage 01/2021
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 02/2019
1	Rupture 01/2019
1	Segmental glomerulosclerosis 01/2019
1	Ureteral Obstruction 01/2019
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2018

Drug/Important Bio-Agent (IBA)

18	Collagen Type IV (Type IV Collagen)IBA 12/2023 - 04/2000
10	CollagenIBA 01/2022 - 09/2009
10	Urea (Carbamide)FDA LinkGeneric 02/2021 - 02/2003
9	CreatinineIBA 01/2023 - 06/2003
7	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2022 - 07/2004
6	Ramipril (Altace)FDA LinkGeneric 06/2021 - 02/2003
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2021 - 03/2012
5	Proteins (Proteins, Gene)FDA Link 12/2023 - 01/2011
5	Collagen ReceptorsIBA 09/2014 - 12/2005
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2017 - 12/2005
4	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2014 - 02/2010
3	Biomarkers (Surrogate Marker)IBA 12/2023 - 11/2013
3	AlbuminsIBA 01/2023 - 08/2017
3	NitrogenIBA 01/2019 - 06/2010
3	CytokinesIBA 01/2012 - 08/2005
2	Sodium-Glucose Transport ProteinsIBA 05/2024 - 01/2023
2	salicylhydroxamic acid (SHAM)IBA 07/2023 - 01/2020
2	Retinaldehyde (Retinal)IBA 06/2023 - 08/2022
2	AntibodiesIBA 01/2021 - 01/2019
2	NPHS2 proteinIBA 01/2019 - 01/2012
2	nephrinIBA 01/2019 - 01/2012
2	EndotoxinsIBA 01/2017 - 01/2011
2	paricalcitol (Zemplar)FDA Link 09/2014 - 05/2014
2	Discoidin Domain Receptor 1IBA 02/2014 - 06/2010
2	Antihypertensive Agents (Antihypertensives)IBA 03/2011 - 08/2005
2	Connective Tissue Growth FactorIBA 03/2011 - 07/2006
2	Transforming Growth Factor beta (TGF-beta)IBA 08/2010 - 07/2006
2	AutoantibodiesIBA 06/2009 - 02/2007
2	Vasopeptidase InhibitorsIBA 12/2005 - 08/2005
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2023
1	finerenoneIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Spironolactone (Aldactone)FDA LinkGeneric 06/2021
1	Mineralocorticoid Receptor AntagonistsIBA 06/2021
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 02/2021
1	SodiumIBA 01/2021
1	Antithrombin IIIIBA 01/2021
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2021
1	DiureticsIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Erythropoietin FDA Link 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	eculizumab FDA Link 01/2021
1	Serum AlbuminIBA 01/2021
1	Abiraterone AcetateIBA 02/2019
1	Prednisone (Sone)FDA LinkGeneric 02/2019
1	abirateroneIBA 02/2019
1	Angiotensin IIIBA 01/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019
1	platelet-derived growth factor C (PDGF-C)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Azathioprine (Imuran)FDA LinkGeneric 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	C-Reactive ProteinIBA 01/2018

Therapy/Procedure

28	Therapeutics 05/2024 - 02/2003
5	Renal Replacement Therapy (Therapies, Renal Replacement) 11/2022 - 04/2012
2	Secondary Prevention 11/2022 - 02/2003
2	Kidney Transplantation 12/2012 - 05/2009
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Critical Care (Surgical Intensive Care) 01/2021
1	Drug Therapy (Chemotherapy) 01/2018